FDA Must Codify Flexibility For Rare Diseases, Coté Says As He Moves To NORD

FDA needs to formalize the flexibility it has employed in its rare disease program, according to Tim Coté, the National Organization for Rare Disorders’ new Chief Medical Officer and former head of the agency’s orphan products development program.